PIC GMP简介翻译
- 格式:docx
- 大小:26.99 KB
- 文档页数:7
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEMEPE 009-14 (Intro) 1 July 2018GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS© PIC/S July 2018 Reproduction prohibited for commercial purposes.Reproduction for internal use is authorised, provided that the source is acknowledged.Editor:PIC/S Secretariat 14 rue du Roveray CH-1207 Genevae-mail: info@ web site: PE 009-14 (Intro)1 July 2018IntroductionINTRODUCTIONGeneralIn order to further facilitate the removal of barriers to trade in medicinal products, to promote uniformity in licensing decisions and to ensure the maintaining of high standards of quality assurance in the development, manufacture and control of medicinal products, the following Guide to Good Manufacturing Practice for Medicinal Products and its Annexes has been adopted.The standards set out herein apply to medicines and similar products intended for human use. It is recommended, however, that the same kind of attention be given to the manufacture of veterinary products. Administrative measures of national health authorities should be directed towards the application of these standards in practice, and any new or amended national regulations for good manufacturing practice should at least meet their level. These standards are also intended to serve manufacturers as a basis for the elaboration of specific rules adapted to their individual needs.It is recognised that there are acceptable methods, other than those described in this Guide, which are capable of achieving the principles of the Guide. This Guide is not intended to place any restraint upon the development of new concepts or new technologies, which have been validated and provide a level of Quality Assurance at least equivalent to those set out in this Guide.The Guide is divided into two parts and a number of annexes which are common to both parts. Part I covers GMP principles for the manufacture of medicinal products. Part II covers GMP for active substances used as starting materials. The annexes provide detail on specific areas of activity. For some manufacturing processes, different annexes will apply simultaneously (e.g. annex on sterile preparations and on radiopharmaceuticals and/or on biological medicinal products). A glossary of some terms used in the Guide has been incorporated after the annexes. A specific glossary for APIs can be found at the end of Part II.HistoryPart I of the PIC/S GMP GuideOriginally, the PIC/S GMP Guide (“PIC Basic Standards” of 1972) derives from the WHO GMP Guide and was further developed in order to comply with stringent manufacturing and health requirements in PIC/S countries, to cover new areas (e.g. biologicals, radiopharmaceuticals, etc.) and to adapt to scientific and industrial technology (e.g. biotech, parametric release etc.). The aim of such improvements was to ensure that high quality medicines were produced in line with the PIC Convention and then the PIC Scheme.In 1989, the EU adopted its own GMP Guide, which – in terms of GMP requirements – was equivalent to the PIC/S GMP Guide. Since that time, the EU and the PIC/S GMP Guides have been developed in parallel and whenever a change has been made to one, the other has been amended so that both Guides are practically identical.PE 009-14 (Intro)1 July 2018IntroductionThere are, however, some differences between the two Guides. These differences are the following: the definition of Pharmaceutical Product (referred to as “Medicinal Product” in this Guide), which is found in Article 1 of the Pharmaceutical Inspection Convention, has been retained; references to the EU Directives, as well as to MRAs, have been deleted; the expression “authorised person” (see Glossary) is used in the PIC/S Guidewhile the expression “Qualified Person” is used in the EU Guide; since not all Participating Authorities under the PIC Scheme are parties to theEuropean Pharmacopoeia Convention, the mention of “European Pharmacopoeia” in the Guide has been amended to read “European or other relevant Pharmacopoeia”.Part II of the PIC/S GMP GuideOn 22 May 2001, the PIC/S Committee adopted the “Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients” (ICH Q7A) developed by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) as a stand-alone guide (PE 007). It is recalled that the first draft of this GMP Guide for APIs was elaborated by PIC/S, before it was transferred to ICH. At its Düsseldorf meeting on 29-30 May 2006, the PIC/S Committee decided to make it Part II of the current Guide.ADOPTION AND ENTRY INTO FORCEAdoption by the Committee of PE 009-14 Entry into force of PE 009-1417-18 April 2018 1 July 2018REVISION HISTORYDate 21 December 200010 August 2001Version NumberReasons for revisionPH 1/97 (Rev.) Revision of Annex 14 Renumbering of all annexes Change in the editor’s address andinsertion of copyright statement Inclusion of revision historyPH 1/97 (Rev. 2) Amendment of para. 42 of Annex 1 Revision of Annex 6 New Annex 15 New Annex 17 Amendment to the glossaryPE 009-14 (Intro)1 July 2018Introduction15 January 20021 September 2003 1 July 2004 1 January 2006 1 June 2006 1 August 2006 5 April 20071 September 200715 January 20091 September 2009 1 January 2013 1 March 2014 1 October 2015 1 January 2017 1 July 2018PH 1/97 (Rev. 3)PE 009-1 PE 009-2 PE 009-3 PE 009-4 PE 009-5 PE 009-6PE 009-7PE 009-8PE 009-9 PE 009-10 PE 009-11 PE 009-12 PE 009-13 PE 009-14 New Annex 4 New Annex 5 Reference to Annex 18 of EC GMPGuide Amendment of Annex 1 (mainlysection 3) Revision of Annex 13 Change in the Editor’s co-ordinates Revision of Chapter 1 Revision of Chapter 6 Corrections to revision of Chapter 6 Revision of Chapter 8 Reorganisation of the PIC/S GMP Guide in Part I, Part II and Annexes Incorporation of PE 007 (APIs guide) as Part II New Annex 19 Revision of the Introduction Change in the Editor’s co-ordinates Revision of General Introduction(“History”) and Introduction to Part II Deletion of footnotes in Chapter 6(Part I) and Annex 13 Revision of Chapter 1 (Part I) Revision of Annex 1 New Annex 20 Revision of Annex 3 Revision of Chapter 4 (Part I) Revision of Annex 6, 7, 11 and 13 Introduction of QRM principals inPIC/S GMP Guide – Part II Revision of Annex 2 and 14 Revision of Annex 15 Revision of Chapters 1, 2, 6 & 7 (Part I) Revision of Chapters 3, 5 & 8 (Part I) Revision of Annex 17PE 009-14 (Intro)1 July 2018。
GMP常见英文缩写AQAI(Automated Quality Assurance Inspection Equipment):在线自动质量保证检查设备API(Active Pharmaceutical Ingredient):活性药物物质,即原料药ANDA(Abbreviated New Drug Application):简化新药申请ADR(Adverse Drug Reaction):不良反应BSE(Bovine Spongiform Encephalopathy):疯牛病BPCS(Business Planning and Control System):业务计划及控制系统BIA(Business impact assessment):商业影响评估cGMP(current Good Manufacturing Practice):现行药品生产质量管理规范CCCD(China Certification Committee for Drugs):中国药品认证委员会CIP(Cleaning In Place):在线清洁CV(Concurrent Validation):同步验证CDER(Center for Drug Evaluation and Research):药品研究与评价中心COA(Certificate Of Analysis):分析报告单CFR(Code of Federal Regulation):(美国)联邦法规CDC(Centers for Disease Control and Prevention):疾病预防控制中心COS/CEP(Certificate of Suitability for European Pharmacopeia):欧洲药典适用性证书CCD(Certification Committee for Drugs):药品认证管理中心CPMP(Committee for Proprietary Medicinal Products):欧洲专利药品委员会CTD(Common Technical Document):通用技术文件CDC(Centers for Disease Control and Prevention):疾病预防控制中心GMP(Good Manufacturing Practice):药品生产质量管理规范ICH(International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use):人用药品注册技术要求国际协调会EU(European Union):欧洲联盟EFPIA(European Federation of Pharmaceutical Industries Associations):欧洲制药工业协会联合会MHW(Ministry of Health and Welfare,Japan):日本厚生省JPMA(Japan Pharmaceutical Manufacturers Association):日本制药工业协会FDA(US Food and Drug Adminiistration):美国食品与药品管理局PRMA(Pharmaceutical Research and Manufacturers of America):美国药物研究和生产联合会WHO(World Health Organization):世界卫生组织IFPMA(International Federation of Pharmaceutical Manufacturers Associations):国际制药工业协会联合会TQC(Total Quality Control),TQM(Total Quality Management):全面质量管理PDCA(Plan,Do,Check,Action):计划,执行,检查,处理QA(Quality Assurance):质量保证QC(Quality Control):质量控制QS(Quality System):质量体系QM(Quality Management):质量管理SOP(Standard Operating Procedure):标准操作规程SMP(Standard Management Procedure):标准管理程序SOR(Standard Operating Record):标准操作记录GEP(Good Engineering Practice):工程设计规范HV AC(Heating Ventilation and Air Conditioning):空调净化系统DQ(Design Qualification):设计确认IQ(Installation Qualification):安装确认OQ(Operational Qualification):运行确认PQ(Performance Qualification):性能确认OOS(Out-Of-Specification):检验不合格;超标PFDS(Process Flow Diagrams):工艺流程图MRA(cMutual Reognition Agreements):现场检查多边认同协议DMF(Drug Master File):EDMF(European Drug Master File)欧盟药物主文件EDQM(European Directorate for Quality Medicines):欧洲药品质量管理局ORA(Office of Regulatory Affairs):药政事务办公室GGPs(Good Guidance Practices):优良指南规范MOA(Method Of Analysis):分析方法VMP(Validation Master Plan):验证主计划VP(Validation Protocol):验证方案MSDS(Material Safety Data Sheet):物料安全技术说明书NDA(New Drug Application):新药申请OTC(Over-the-counter):非处方INN(International Nonproprietary Name)国际非专有名称USP(the united state pharmacopeia):美国药典NF(National Formulary):(美国)国家药品集GAP(Good Agricultural Practice):中药材种植管理规范GCP(Good Clinical Practice):药物临床试验质量管理规范GLP(Good Laboratory Practice):药物实验室管理规范GSP(Good Supply Practice):药品经营质量管理规范GUP(Good Use Practice):药品使用质量管理规范SM(Starting Material):起始物料PMF(Plant Master File);SMF(Site Master File):工厂主文件EDL(List of Essential Drugs):基本药物目录PI(Package Insert):说明书PCT(Patent Cooperation Treaty):专利合作条约PPAC(Patent Protection Association of China):中国专利保护协会PIC(Person In Charge):负责人PDS(Pharmaceutical Development Services):整体新药研发机构SPC(Summary of Product Characteristics):产品特性摘要。
PICS发布针对GMP无菌要求的解释文件PIC/S发布针对GM无菌要求的解释文件国际医药品稽查协约组织(PIC/S) 药品优良制造规范指导手册》由于无菌产品的特殊性〜GMP寸无菌产品要求从来都是药政部门与企业关注的重点。
1月8日〜药品检查协定和药品检查合作计划组织,PIC/S,发布了针对PIC/S-GMP第一附件,无菌药品制造,2008年修订版中重点条款的解释文件的新修订文本上一个修订文本是在2009年11 月24日发布的〜于2009年12月1日开始实施,。
这次发布的文件修订本已于2010年1月1日实施〜体现出此文件对药政官方与企业的重要性。
本报第一时间将新文本及其解释部分的译文予以刊登〜望能给相关企业以参考和帮助。
PIC/S 组织的成员国不仅包括欧盟大多数国家〜也包括了一部分欧洲的非欧盟国家〜例如瑞士与挪威〜还包括亚洲的马来西亚、新加坡〜北美洲的加拿大〜大洋洲的澳大利亚〜南美洲的阿根廷以及非洲的南非等国家。
PIC/S组织有四个合作方〜分别是欧洲药品质量和健康保障局,EDQM,欧盟药品管理局,EMEA,、联合国儿童基金会,UNICEF,以及世界卫生组织,WHO。
从某种意义上说〜PIC/S的GMP以及大多数PIC/S成员国的GMPf欧盟GMP都属同一个系列。
由于PIC/S成员国中既有发达国家〜也有发展中国家〜可见PIC/S-GMP具有广泛的国际基础。
新修订文件的发布〜给PIC/S组织的成员国在实施PIC/S-GMP第一附件过程中产生的一些具体问题提供了官方的解释。
这个文件发布后〜引起了我国业界的广泛关注〜业内人士普遍认为〜这个文件对我国药企在国外注册与认证有重大的影响。
理念与现实同步在GMP文件的文本上〜PIC/S-GMP与欧盟GM基本上保持同步修订〜其附件与条款的内容也基本相同,除了欧盟GM啲附件16 “产品放行人与批放行”没有被PIC/S批准外,。
PIC/S也表示〜“ PIC/S-GMP旨南第一附件与欧盟GMP旨南第一附件完全相同”〜“这两个指南在GMPh要求一致”。
ISO(International Organization for Standardization):国际标准化组织日常办事机构是中央秘书处,设在瑞士日内瓦WHO(World Health Organization):世界卫生组织是联合国属下的专门机构,国际最大的公共卫生组织,总部设于瑞士日内瓦PIC/S(Pharmaceutical Inspection Convention/Pharmaceutical Inspection Cooperation Scheme):国际医药品稽查协约组织由欧洲自由贸易区(EFTA)组建ICH(International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use):人用药物注册技术要求国际协调会由欧盟(EU)、欧洲制药工业协会联合会(EFPIA)、日本厚生省(MHW)、日本制药工业协会(JPMA)、美国FDA、美国药物研究生产联合会(PRMA)等机构组成WHO、EFTA、加拿大卫生保健局(CHPB)为观察员ISPE(International Society for Pharmaceutical Engineering):国际制药工程协会是致力于培训制药领域专家并提升制药行业水准的世界最大的非盈利性组织之一,在美国坦帕州设有全球总部,在布鲁塞尔设有欧洲总部,亚洲总部在新加坡HHS(United States Department of Health and Human Services):美国卫生及公共服务部(美国卫生部)FDA(Food and Drug Administration):美国食品药品监督管理局(HHS下属机构)PDA(Parenteral Drug Association):美国注射剂协会EPA(Environmental Protection Agency):美国国家环境保护局CDER(Center for Drug Evaluation and Research):FDA药物评价与研究中心EMEA(The European Agency for the Evaluation of Medicinal Products):欧洲药物评审组织MHW(Ministry of Health and Welfare):日本厚生省,现改为厚生劳动省MHLW(Ministry of Health, Labor and Welfare),负责医疗卫生和社会保障的主要部门D&B(Dun & Bradstreet):邓白氏公司DUNS(Data Universal Numbering System):邓白氏公司提供的唯一的公司代号,用于信用评级等在SMF文件中会用到GMP(Good Manufacturing Practice):药品良好生产规范cGMP(Current Good Manufacture Practices):动态药品生产管理规范,即现行的GLP(Good Laboratory Practice):药物非临床研究质量管理规范,及优良实验室规范GSP(Good Supplying Practice):药品经营质量管理规范,及良好的药品供应规范GAP(Good Agricultural Practice for Chinese Crude Drugs):中药材生产质量管理规范GDP(Good Documentation Practice):良好文件管理GEP(Good Engineering Practice):工程设计规范GAMP(Good Automated Manufacturing Practice):优良自动化生产规范USP(united states pharmacopeia):美国药典EP(European Pharmacopeia):欧洲药典JP(Japanese Pharmacopoeia):日本药典CFR(Code of Federal Regulations):美国联邦法律CFR 21 Part 11(Code of Federal Registry Part11):联邦法规法律标题21第11部分CEP/COS(Certificate of Suitability to the monographs of European Pharmacopoeia):欧洲药典适应性认证证书CEP认证,COS证书CTD(Common Technical Document):国际注册用常规技术文件CTD文件是国际公认的文件编写格式,用来制作一个向药品注册机构递交的结构完善的注册申请文件EHS(Environment、Health、Safety):环境-健康-安全管理体系HACCP(Hazard Analysis and Critical Control Point):(保健食品)危害分析和关键控制点REACH(REGULATION concerning the Registration, Evaluation, Authorization and Restriction of Chemicals):欧盟规章《化学品注册、评估、许可和限制》,欧盟建立的,并于2007年6月1日起实施的化学品监管体系ICH-Q1A:新原料药和制剂的稳定性试验ICH-Q1B:稳定性试验:新原料药和制剂的光稳定性试验ICH-Q1C:稳定性试验:新剂型的要求ICH-Q1D:新原料药和制剂的稳定性试验的括号法和矩阵法设计ICH-Q1E:稳定性数据的评价ICH-Q1F:气候带Ⅲ和Ⅳ注册申请的稳定性数据ICH-Q2A:分析步骤验证:正文ICH-Q2B:分析步骤验证:方法学ICH-Q3A:原料药中的杂质ICH-Q3B:新制剂中的杂质ICH-Q3C:杂质;残留溶剂的指导原则ICH-Q4 :药典ICH-Q4A :药典的同一化ICH-Q4B:各地区使用的药典正文评估和建议ICH-Q5A:来源于人或动物细胞系的生物技术产品的病毒安全性评价ICH-Q5B:生物技术产品的质量:rDNA衍生蛋白质产品生产细胞的表达构建体分析ICH-Q5C:生物技术产品的质量:生物制品/生物技术产品的稳定性试验ICH-Q5D:用于生物技术产品及生物制品生产的细胞基质的来源和鉴定ICH-Q5E:生物技术产品/生物制品在工艺变更时的可比性ICH-Q6A:质量标准新原料药和制剂的检测以及可接受标准:化学物质ICH-Q6B:质量标准:生物技术产品及生物制品的检测方法和可接受标准ICH-Q7 :原料药良好制造规范(ICH-Q7A的新版)ICH-Q7A:原料药的GMP规范ICH-Q8 :药物研发指南ICH-Q9 :质量风险管理ICH- Q10(PQS):药物质量体系QA(Quality Assurance):质量保证QC(Quality Control):质量控制QRM(Quality Risk Management):质量风险管理IPC(Inproceics Quality Control):制程品质控制/中控OOS(Out of Specification):检验结果超标OOT(Out of Trend):超趋势结果OOL(Out of Limit):超出极限的结果,如温湿度等OOE(Out of Expectation):超期望结果SAL(Sterility Assurance Level):无菌保证水平灭菌后微生物的存活概率的负对数,要求≥6D值:杀灭90%的微生物所需要的时间,D值越大,微生物死亡越难,D值与细菌的耐热性成正比Z值:指灭菌时间减少到原来的10%所需要升高的温度或是相同的灭菌时间内杀死99%的微生物所需要提高的温度F值:为一定温度下,给定Z值所产生的灭局效果与参比温度T0下给定Z值所产生的灭菌效果相同时所相当的时间F值用于干热灭菌F0值:为一定温度下,Z值为10℃产生的灭菌效果与120℃,Z值为10℃时产生的灭菌效果相当的时间,t分钟内的灭菌效果相当于120℃下灭菌F0分钟的效果F0被称为标准灭菌时间,用于热压灭菌LRV:除菌过滤的对数下降值LRV=lgN0-lgNSOP(Standard Operation Procedure):标准操作规程DMF(Drug Master File):药品主文件SMF(Site Master File):工厂主文件URS(User Requirement Specification):用户需求标准FS(Functional Specification):功能标准DS(Design Specification):设计标准DQ(Design Qualification):设计确认IQ(Installation Qualification):安装确认OQ(Operational Qualification):运行确认PQ(Performance Qualification):性能确认RQ(Requalification):再确认CAPA(Corrective Action & Preventive Action):纠正预防系统,Q10的四大要素之一QbD(Quality by Design):质量源于设计COA(Certificate of Analysis):分析证书/检验报告书/检验报告单BPR(Batch Production Record):批生产记录API(Active Pharmaceutical Ingredients):药物活性成分,通常指的原料药。
国际组织ISO(International Organization for Standardization):国际标准化组织日常办事机构是中央秘书处,设在瑞士日内瓦WHO(World Health Organization):世界卫生组织是联合国属下的专门机构,国际最大的公共卫生组织,总部设于瑞士日内瓦PIC/S(Pharmaceutical Inspection Convention/Pharmaceutical Inspection Cooperation Scheme):国际医药品稽查协约组织由欧洲自由贸易区(EFTA)组建ICH(International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human U se):人用药物注册技术要求国际协调会由欧盟(EU)、欧洲制药工业协会联合会(EFPIA)、日本厚生省(MHW)、日本制药工业协会(JPMA)、美国FDA、美国药物研究生产联合会(PRMA)等机构组成WHO、EFTA、加拿大卫生保健局(CHPB)为观察员ISPE(International Society for Pharmaceutical Engineering):国际制药工程协会是致力于培训制药领域专家并提升制药行业水准的世界最大的非盈利性组织之一,在美国坦帕州设有全球总部,在布鲁塞尔设有欧洲总部,亚洲总部在新加坡HHS(United States Department of Health and Human Services):美国卫生及公共服务部(美国卫生部)FDA(Food and Drug Administration):美国食品药品监督管理局(HHS下属机构) PDA(Parenteral Drug Association):美国注射剂协会 EPA(Environmental Protection Agency):美国国家环境保护局CDER(Center for Drug Evaluation and Research):FDA药物评价与研究中心EMEA(The European Agency for the Evaluation of Medicinal Products):欧洲药物评审组织MHW(Ministry of Health and Welfare):日本厚生省,现改为厚生劳动省MHLW (Ministry of Health, Labor and Welfare),负责医疗卫生和社会保障的主要部门 D&B(Dun & Bradstreet):邓白氏公司DUNS(DataUniversal Numbering System):邓白氏公司提供的唯一的公司代号,用于信用评级等在SMF文件中会用到ATCC(American Type Culture Collection):美国模式培养物集存库 ASTM(American Society for Testing Materials):美国材料与试验协会法规GMP(Good Manufacturing Practice):药品良好生产规范cGMP(Current Good Manufacture Practices):动态药品生产管理规范,即现行的 GLP(Good Laboratory Practice):药物非临床研究质量管理规范,及优良实验室规范 GSP(Good Supplying Practice):药品经营质量管理规范,及良好的药品供应规范 GAP(Good Agricultural Practice for Chinese Crude Drugs):中药材生产质量管理规范 GDP (Good Documentation Practice):良好文件管理 GEP(Good Engineering Practice):工程设计规范GAMP(Good Automated Manufacturing Practice):优良自动化生产规范 USP(united states pharmacopeia):美国药典 EP(European Pharmacopeia):欧洲药典 JP(Japanese Pharmacopoeia):日本药典 CFR(Code of Federal Regulations):美国联邦法律CFR 21 Part 11(Code of Federal Registry Part11):联邦法规法律标题21第11部分 CEP/COS (Certificate of Suitability to the monographs of European Pharmacopoeia):欧洲药典适应性认证证书CEP认证,COS 证书CTD(Common Technical Document):国际注册用常规技术文件CTD文件是国际公认的文件编写格式,用来制作一个向药品注册机构递交的结构完善的注册申请文件 EHS(Environment、Health、Safety):环境-健康-安全管理体系HACCP(Hazard Analysis and Critical Control Point):(保健食品)危害分析和关键控制点 REACH (REGULATION concerning the Registration, Evaluation, Authorization and Restriction of Chemicals):欧盟规章《化学品注册、评估、许可和限制》,欧盟建立的,并于2007年6月1日起实施的化学品监管体系ICH法规ICH-Q1A:新原料药和制剂的稳定性试验ICH-Q1B:稳定性试验:新原料药和制剂的光稳定性试验ICH-Q1C:稳定性试验:新剂型的要求ICH-Q1D:新原料药和制剂的稳定性试验的括号法和矩阵法设计ICH-Q1E:稳定性数据的评价ICH-Q1F:气候带Ⅲ和Ⅳ注册申请的稳定性数据ICH-Q2A:分析步骤验证:正文ICH-Q2B:分析步骤验证:方法学ICH-Q3A:原料药中的杂质ICH-Q3B:新制剂中的杂质ICH-Q3C:杂质;残留溶剂的指导原则ICH-Q4:药典ICH-Q4A:药典的同一化ICH-Q4B:各地区使用的药典正文评估和建议ICH-Q5A:来源于人或动物细胞系的生物技术产品的病毒安全性评价ICH-Q5B:生物技术产品的质量:rDNA衍生蛋白质产品生产细胞的表达构建体分析ICH-Q5C:生物技术产品的质量:生物制品生物技术产品的稳定性试验ICH-Q5D:用于生物技术产品及生物制品生产的细胞基质的来源和鉴定ICH-Q5E:生物技术产品生物制品在工艺变更时的可比性ICH-Q6A:质量标准新原料药和制剂的检测以及可接受标准:化学物质ICH-Q6B:质量标准:生物技术产品及生物制品的检测方法和可接受标准ICH-Q7:原料药良好制造规范(ICH-Q7A的新版)ICH-Q7A:原料药的GMP规范ICH-Q8:药物研发指南ICH-Q9:质量风险管理ICH- Q10(PQS):药物质量体系ICH-Q11:原料药研发与生产常见术语QA(Quality Assurance):质量保证QC(Quality Control):质量控制CQA(Critical Quality Attribute):关键质量属性QRM(Quality Risk Management):质量风险管理IPC(InproceicsQuality Control):制程品质控制/中控OOS(Out of Specification):检验结果超标OOT(Out of Trend):超趋势结果OOL(Out of Limit):超出极限的结果,如温湿度等OOE(Out of Expectation):超期望结果SOP(Standard Operation Procedure):标准操作规程DMF(Drug Master File):药品主文件SMF(Site Master File):工厂主文件URS(User Requirement Specification):用户需求标准FAT(Factory Acceptance Test):工厂验收测试SAT(Site Acceptance Test):现场验收测试FS(Functional Specification):功能标准DS(Design Specification):设计标准DQ(Design Qualification):设计确认IQ(Installation Qualification):安装确认OQ(Operational Qualification):运行确认PQ(Performance Qualification):性能确认RQ(Requalification):再确认CAPA(Corrective Action & Preventive Action):纠正预防系统,Q10的四大要素之一QbD(Quality byDesign):质量源于设计PMC(Product Material Control):生产物料控制PC生产控制;MC物料控制CMC(Chemistry and manufacture control):生产和化学控制APR(Annual Products Review):年度质量回顾CNC(Controlled Non-Classified Area):受控非洁净区应用技术APS(Aseptic Processing Simulation):培养基模拟灌装CIP(Cleaning in Place):原位清洗(全自动,如针剂配制系统)WIP(Washing in Place):在线清洁(半自动,需要手动的拆卸,如流化床)SIP(Sterilization in Place):在线灭菌BFS(Blowing Filling and Sealing):吹-灌-封PA T(Process Analytical Technology):过程分析技术PLC(Programmable Logic Controller):可编程逻辑控制EDI(Electrodeionization):一种制备纯化水的离子交换技术MAC(Minimum Acceptable Cycle):最低可接受程序SAM(Steam-Air Mixture):蒸汽空气混合气体灭菌程序WIT(Water IntrusionTest):水侵入测试(东富龙疏水性滤器的在线进行完整性测试的方法) BP(Bubble Point Test):起跑点试验FF(Forward Flow/Diffusive Flow):前进流、扩散流试验HPLC(High Performance Liquid Chromatography):高效液相色谱GC(Gas Chromatography):气相色谱FTIR(Fourier Transform Infrared spectroscopy):傅氏转换红外线光谱分析仪MS(Mass Spectroscopy):质谱LC/MS:液质联用GC/MS:气质联用TOC(Total Organic Carbon):总有机碳NVR(NonvolatileResidue):不挥发残留物RFS(Ready for Sterilization):免洗胶塞RFU(Ready for Use):即用胶塞物品名称SVP(Small V olume Parenteral):小容量注射剂 LVP(Large Volume Parenteral):大容量注射剂 APA (Aseptic Processing Area):无菌区P&ID(Piping and Instrument Diagram):工艺管道仪表流程图 PFD(Process Flow Diagram):工艺流程图 UFD (Utility Flow Diagram):公用工程流程图HV AC(Heating Ventilation Air Conditioning):供热空气调节净化系统 HEPA(High Efficiency Particulate Air Filter):高效过滤器 FFU(Fan Filter Units):风机滤器单元 AHU(Air Handling Unit):空气处理单元COA(Certificate of Analysis):分析证书/检验报告书/检验报告单 BPR(Batch Production Record):批生产记录API(Active Pharmaceutical Ingredients):药物活性成分,通常指的原料药 WFI(Water for Injection):注射用水DOP:为邻苯二甲酸二辛酯,HEPA检漏用的气溶胶 PAO:聚-α-烯烃,HEPA检漏用的气溶胶 IBC (IntermediateBulkContainer):中型散装容器 FBD(Fluid Bed Dryer):流化床IRTD(IntelligentResistance Temperature Detector):智能热电阻温度探头,标准温度探头 SV(Solenoid Valve):电磁阀FV:气动阀P/HG(Porous/Hard Goods Loads):多孔/坚硬装载,包括过滤器、胶塞、软管、拖把、工作服、塞子、清洁器具或设备的更换部件。
澳大利亚TGA药物良好生产操作规范导言 (4)解释 (4)第一章质量管理 (5)原则 (5)质量保证 (5)良好的生产操作规范 (5)质量控制 (6)第二章人员 (7)原则 (7)一般原理 (7)关键人员 (7)培训 (8)个人卫生 (8)第三章厂房与设备 (9)原则 (9)厂房 (9)原则 (9)生产区 (9)贮存区 (10)质量控制区 (10)设备 (10)第四章文件 (12)原则 (12)一般原理 (12)必备文件 (12)制造手册和生产指令 (13)包装指令 (14)批生产记录 (14)批包装记录 (14)程序和记录 (15)第五章生产过程 (17)原则 (17)一般原理 (17)生产过程中交叉污染的预防 (17)验证 (18)起始物料 (18)生产操作中间体和未包装产品 (19)包装材料 (19)包装 (19)成品 (20)不合格品、返工与回收产品 (20)第六章质量控制 (21)原则 (21)一般原理 (21)优良的质控化验室 (21)文件 (21)取样 (22)检测 (22)第七章合同加工与分析 (24)原则 (24)一般原理 (24)合同的提供者(甲方) (24)合同的接受者(乙方) (24)合同 (24)第八章投诉与产品召回 (26)原则 (26)投诉 (26)召回 (26)第九章自检 (27)原则 (27)附录 (28)附录八:起始物料与包装材料的取样 (28)原则 (28)人员 (28)起始物料 (28)包装材料 (29)附录十五:确认与验证 (29)原则 (29)验证计划 (29)文件 (29)确认 (30)过程确认 (30)清洁验证 (32)变更控制 (32)再验证 (32)术语 (32)附录十六:资质人员和批放行 (33)附录十七:参数的放行 (33)1、原则 (33)2、参数放行 (33)灭菌产品的参数让步 (33)术语 (33)附录十八:原料药的GMP指南 (33)术语 (33)导言为了在整个欧洲更好地推动药品贸易壁垒的消除,更好地促进药品生产许可证的一体化以及在药品的研发、生产和控制的过程中产品的质量始终维持在一个高标准的状态,对PIC和PIC/S所应用的GMP进行了协调。
GMP英语PIC/S的全称为:Pharmaceutical Inspection Convention/Pharmaceutical Inspection Cooperation Scheme, PIC/S(制药检查草案), 药品检查协会(PIC/S) ,也有人称PIC/S为医药审查会议/合作计划(PIC/S)PIC的权威翻译:药品生产检查相互承认公约API(Active Pharmaceutical Ingrediet) 原料药又称:活性药物组分AirLock 气闸Authorized Person 授权人Batch/Lot 批次Batch Number/Lot-Number 批号;Batch Numbering System 批次编码系统;Batch Records 批记录;Bulk Product 待包装品;Calibration 校正;Clean area洁净区;Consignmecnt(Delivery)托销药品。
FDA(FOOD AND DRUG ADMINISTRA TION):(美国)食品药品管理局IND(INVESTIGA TIONAL NEW DRUG):临床研究申请(指申报阶段,相对于NDA而言);研究中的新药(指新药开发阶段,相对于新药而言,即临床前研究结束)NDA(NEW DRUG APPLICA TION):新药申请ANDA(ABBREVIATED NEW DRUG APPLICATION):简化新药申请TREATMENT IND:研究中的新药用于治疗ABBREVIATED(NEW)DRUG:简化申请的新药DMF(DRUG MASTER FILE):药物主文件(持有者为谨慎起见而准备的保密资料,可以包括一个或多个人用药物在制备、加工、包装和贮存过程中所涉及的设备、生产过程或物品。
只有在DMF持有者或授权代表以授权书的形式授权给FDA,FDA在审查IND、NDA、ANDA时才能参考其内容)HOLDER:DMF持有者CFR(CODE OF FEDERAL REGULATION):(美国)联邦法规PANEL:专家小组BA TCH PRODUCTION:批量生产;分批生产BA TCH PRODUCTION RECORDS:生产批号记录POST-OR PRE- MARKET SURVEILLANCE:销售前或销售后监督INFORMED CONSENT:知情同意(患者对治疗或受试者对医疗试验了解后表示同意接受治疗或试验)PRESCRIPTION DRUG:处方药OTC DRUG(OVER—THE—COUNTER DRUG):非处方药GMP文件常见缩写ABPI Association of the British Pharmaceutical IndustryADR Adverse Drug ReactionAE Adverse EventAIM Active Ingredient ManufacturerANDA Abbreviated New Drug ApplicationANOV A Analysis of VarianceASM: Active Substance ManufacturerATC Anatomical Therapeutic ChemicalATX Animal Test Exemption CertificateBAN British Approved NameBIRA British Institute of Regulatory AffairsBNF British National FormularyBP British PharmacopoeiaC of A Certificate of AnalysisC of S Certificate of SuitabilityCENTRE FOR DRUG EV ALUATION (CDE)Centre for Pharmaceutical Administration (CPA)CMS Concerned Member StateCMS每个成员国COS Certificate of SuitabilityCPMP Committee for Proprietary Medicinal ProductsCRA Clinical Research AssociateCRF Case Report FormCRO Contract Research OrganisationCTA Clinical Trial ApplicationCTC Clinical Trial CertificateCTD Common Technical DocumentCTX Clinical Trials ExemptionDDD Defined Daily DoseDGC Daily Global ComparisonDIA Drug Information AssociationDMF Drug Master FileDrug Registration Branch (DR, Product Evaluation & Registration Division, CPAEDQM (European Directorate for the Quality of Medicines) 欧洲联盟药品质量指导委员会EEA 欧洲经济地区EGMA European Generics Medicine AssociationELA Established Licence ApplicationEMEA European Medicines Evaluation AgencyEMEA (European Agency for the Evaluation of Medicinal Products)欧洲联盟药品评价机构EP European PharmacopoeiaEPAR European Public Assessment ReportsESRA European Society of Regulatory AffairsEuropean Pharmacopoeia Commission 欧洲药典委员会FDAFDA Food and Drug Administrationfinal evaluation report (FER)free sale certificates (FSCs)GCP Good Clinical PracticeGCP药品临床研究管理规范GLP Good Laboratory PracticeGLP 药品临床前安全性研究质量管理规范GMP Good Manufacturing PracticeGMP 药品生产质量管理规范GSP药品销售管理规范Health Sciences Authority (HSA)HSA’s Medicines Advisory Committee (MAC)IB Investigators BrochureICH International Conference for HarmonisationIDMC Independent Data-Monitoring CommitteeIEC Independent Ethics CommitteeIND Investigational New DrugINN International Non-proprietary Name International Conference on Harmonisation (ICH)IPC In Process ControlIRB Institutional Review BoardLICENCE HOLDERMA Marketing AuthorisationMAA Marketing Authorisation ApplicationMAA上市申请MAH Marketing Authorisation HolderMAH 销售许可持有者MCA Medicines Control AgencyMHW Ministry of Health and Welfare (Japan)MR Mutual RecognitionMRA 美国与欧盟的互认协议MRAs (Mutual Recognition Agreements) 互相認證同意MRFG Mutual Recognition Facilitation GroupMRP Mutual Recognition ProcedureNAS New Active SubstanceNCE New Chemical EntityNDA New Drug Applicationnew chemical entities (NCEs)new drug applications (NDAs)NSAID Non Steroidal Anti Inflammatory DrugNTA Notice To ApplicantsOOS Out of SpecificationOTC Over The CounterPAGB Proprietary Association of Great BritainPh Eur European PharmacopoeiaPIL Patient Information LeafletPL Product LicencePOM Prescription Only MedicinePRODUCT OWNERPSU Periodic Safety UpdatesQA Quality AssuranceQC Quality ControlRAJ Regulatory Affairs JournalRMS Reference Member StateRMS相互认可另一成员国RSD Relative Standard DeviationRx Prescription OnlySAE Serious Adverse EventSMF Site Master FileSOP Standard Operating ProcedureSOP (STANDARD OPERATION PROCEDURE)标准运作程序SPC/SmPC Summary of Product Characteristicssummary of product characteristics(SPC)Therapeutic Goods Administration (TGA)USP US PharmacopoeiaVMF Veterinary Master FileVPC Veterinary Products CommitteeA.A.A Addition and Amendments 增补和修订AC Air Conditioner 空调器ADR Adverse Drug Reaction 药物不良反应AFDO Association of Food and Drug Officials 食品与药品官员协会(美国)ACC Accept 接受AQL Acceptable Quality Level 合格质量标准ADNA Abbreviated New Drug Application 简化的新药申请BOM Bill of Material 物料清单BPC Bulk pharmaceutical Chemiclls 原料药CBER Center for Biologics Evaluation Research 生物制品评价与研究中心CFU Colony Forming Unet 菌落形成单位DMF Drug Master File 药品管理档案CDER Cemter for Drug Evaluation amd Research 药物评价与研究中心CI Corporate Identity (Image) 企业识别(形象)CIP Cleaning in Place 在线清洗CSI Consumer Safety Insepctor 消费者安全调查员CLP Cleaning Line Procedure 在线清洗程序DAL Defect Action Level 缺陷作用水平DEA Drug Enforcement Adminestration 管制药品管理DS Documentation Systim 文件系统FDA Food and Drug Administration 食品与药品管理局(美国)GA TT General Agreemernt on Tariffs and Trade 关贸总协会GMP Good Manufacturing Practice Gvp 药品生质量管理规范GCP Good Clinical Practice 药品临床实验管理规范GLP Good Laboratory Practice 实验室管理规范GSP Good Supply Practice 药品商业质量规范GRP Gook RaTAIL Practice 药品零业质量管理规范GAP Good Agriculture Practice 药材生产管理规范GVP Gook Validation Prctice 验证管理规范GUP Gook Use Practice 药品重用规范HV AC Heating Ventilation Air Conditioning 空调净化系统ISO Intematonal Organization for Standardization 车际标准化组织MOU Memorandum of Understanding 谅解备忘录PF Porduction File 生产记录用表格OTC Over the Counter (Drug) 非处方药品PLA Product License Application 产品许可申请QA Quality Assurance 质量保证QC Quality Control 质量控制QMP Quality Management Procedure 质量管理程序SDA State Drug Administration 国家药品监督管理局SMP Standard Managmert Procedure 标准管理程序SOP Standard Operating Procedure 标准操作程序TQC Tatal Quality Control 全面质量管理USA Uneted States Pharmacopeia 美国药典。
GMP英语1.ABBREVIATED(NEW)DRUG:简化申请的新药2.AirLock 气闸3.ANDA(ABBREVIATED NEW DRUG APPLICATION):简化新药申请4.API(Active Pharmaceutical Ingrediet) 原料药又称:活性药物组分5.Authorized Person 授权人6.Batch Number/Lot-Number 批号7.Batch Numbering System 批次编码系统8.BATCH PRODUCTION RECORDS:生产批号记录9.BATCH PRODUCTION:批量生产;分批生产10.Batch Records 批记录11.Batch/Lot 批次12.Bulk Product 待包装品13.Calibration 校正14.CFR(CODE OF FEDERAL REGULATION):(美国)联邦法规15.Clean area 净区16.Consignmecnt(Delivery)托销药品17.DMF(DRUG MASTER FILE):药物主文件(持有者为谨慎起见而准备的保密资料,可以包括一个或多个人用药物在制备、加工、包装和贮存过程中所涉及的设备、生产过程或物品。
只有在DMF持有者或授权代表以授权书的形式授权给FDA,FDA在审查IND、NDA、ANDA时才能参考其内容)18.FDA(FOOD AND DRUG ADMINISTRATION):(美国)食品药品管理局19.HOLDER:DMF持有者20.IND(INVESTIGATIONAL NEW DRUG):临床研究申请(指申报阶段,相对于NDA而言);研究中的新药(指新药开发阶段,相对于新药而言,即临床前研究结束)RMED CONSENT:知情同意(患者对治疗或受试者对医疗试验了解后表示同意接受治疗或试验)22.NDA(NEW DRUG APPLICATION):新药申请23.OTC DRUG(OVER—THE—COUNTER DRUG):非处方药24.PANEL:专家小组25.PIC/S的全称为:Pharmaceutical Inspection Convention/Pharmaceutical InspectionCooperation Scheme, PIC/S(制药检查草案), 药品检查协会(PIC/S) ,也有人称PIC/S 为医药审查会议/合作计划(PIC/S)26.PIC的权威翻译:药品生产检查相互承认公约27.POST-OR PRE- MARKET SURVEILLANCE:销售前或销售后监督28.PRESCRIPTION DRUG:处方药29.TREATMENT IND:研究中的新药用于治疗GMP文件常见缩写ABPI Association of the British Pharmaceutical IndustryADR Adverse Drug ReactionAE Adverse EventAIM Active Ingredient ManufacturerANDA Abbreviated New Drug ApplicationANOVA Analysis of VarianceASM: Active Substance ManufacturerATC Anatomical Therapeutic ChemicalATX Animal Test Exemption CertificateBAN British Approved NameBIRA British Institute of Regulatory AffairsBNF British National FormularyBP British PharmacopoeiaC of A Certificate of AnalysisC of S Certificate of SuitabilityCENTRE FOR DRUG EVALUATION (CDE)Centre for Pharmaceutical Administration (CPA)CMS Concerned Member State 每个成员国COS Certificate of SuitabilityCPMP Committee for Proprietary Medicinal ProductsCRA Clinical Research AssociateCRF Case Report FormCRO Contract Research OrganisationCTA Clinical Trial ApplicationCTC Clinical Trial CertificateCTD Common Technical DocumentCTX Clinical Trials ExemptionDDD Defined Daily DoseDGC Daily Global ComparisonDIA Drug Information AssociationDMF Drug Master FileDrug Registration Branch (DR, Product Evaluation & Registration Division, CPA EDQM (European Directorate for the Quality of Medicines) 欧洲联盟药品质量指导委员会EEA 欧洲经济地区EGMA European Generics Medicine AssociationELA Established Licence ApplicationEMEA European Medicines Evaluation AgencyEMEA (European Agency for the Evaluation of Medicinal Products)欧洲联盟药品评价机构EP European PharmacopoeiaEPAR European Public Assessment ReportsESRA European Society of Regulatory Affairs European Pharmacopoeia Commission 欧洲药典委员会FDAFDA Food and Drug Administrationfinal evaluation report (FER)free sale certificates (FSCs)GCP Good Clinical PracticeGCP药品临床研究管理规范GLP Good Laboratory PracticeGLP 药品临床前安全性研究质量管理规范GMP Good Manufacturing PracticeGMP 药品生产质量管理规范GSP药品销售管理规范Health Sciences Authority (HSA)HSA’s Medicines Advisory Committee (MAC)IB Investigators BrochureICH International Conference for Harmonisation IDMC Independent Data-Monitoring CommitteeIEC Independent Ethics CommitteeIND Investigational New DrugINN International Non-proprietary Name International Conference on Harmonisation (ICH) IPC In Process ControlIRB Institutional Review BoardLICENCE HOLDERMA Marketing AuthorisationMAA Marketing Authorisation ApplicationMAA上市申请MAH Marketing Authorisation HolderMAH 销售许可持有者MCA Medicines Control AgencyMHW Ministry of Health and Welfare (Japan)MR Mutual RecognitionMRA 美国与欧盟的互认协议MRAs (Mutual Recognition Agreements) 互相認證同意MRFG Mutual Recognition Facilitation Group MRP Mutual Recognition ProcedureNAS New Active SubstanceNCE New Chemical EntityNDA New Drug Applicationnew chemical entities (NCEs)new drug applications (NDAs)NSAID Non Steroidal Anti Inflammatory DrugNTA Notice To ApplicantsOOS Out of SpecificationOTC Over The CounterPAGB Proprietary Association of Great BritainPh Eur European PharmacopoeiaPIL Patient Information LeafletPL Product LicencePOM Prescription Only MedicinePRODUCT OWNERPSU Periodic Safety UpdatesQA Quality AssuranceQC Quality ControlRAJ Regulatory Affairs JournalRMS Reference Member StateRMS相互认可另一成员国RSD Relative Standard DeviationRx Prescription OnlySAE Serious Adverse EventSMF Site Master FileSOP Standard Operating ProcedureSOP (STANDARD OPERATION PROCEDURE)标准运作程序SPC/SmPC Summary of Product Characteristicssummary of product characteristics(SPC)Therapeutic Goods Administration (TGA)USP US PharmacopoeiaVMF Veterinary Master FileVPC Veterinary Products CommitteeA.A.A Addition and Amendments 增补和修订AC Air Conditioner 空调器ADR Adverse Drug Reaction 药物不良反应AFDO Association of Food and Drug Officials 食品与药品官员协会(美国)ACC Accept 接受AQL Acceptable Quality Level 合格质量标准ADNA Abbreviated New Drug Application 简化的新药申请BOM Bill of Material 物料清单BPC Bulk pharmaceutical Chemiclls 原料药CBER Center for Biologics Evaluation Research 生物制品评价与研究中心CFU Colony Forming Unet 菌落形成单位DMF Drug Master File 药品管理档案CDER Cemter for Drug Evaluation amd Research 药物评价与研究中心CI Corporate Identity (Image) 企业识别(形象)CIP Cleaning in Place 在线清洗CSI Consumer Safety Insepctor 消费者安全调查员CLP Cleaning Line Procedure 在线清洗程序DAL Defect Action Level 缺陷作用水平DEA Drug Enforcement Adminestration 管制药品管理DS Documentation Systim 文件系统FDA Food and Drug Administration 食品与药品管理局(美国)GATT General Agreemernt on Tariffs and Trade 关贸总协会GMP Good Manufacturing Practice Gvp 药品生质量管理规范GCP Good Clinical Practice 药品临床实验管理规范GLP Good Laboratory Practice 实验室管理规范GSP Good Supply Practice 药品商业质量规范GRP Gook RaTAIL Practice 药品零业质量管理规范GAP Good Agriculture Practice 药材生产管理规范GVP Gook Validation Prctice 验证管理规范GUP Gook Use Practice 药品重用规范HVAC Heating Ventilation Air Conditioning 空调净化系统ISO Intematonal Organization for Standardization 车际标准化组织MOU Memorandum of Understanding 谅解备忘录PF Porduction File 生产记录用表格OTC Over the Counter (Drug) 非处方药品PLA Product License Application 产品许可申请QA Quality Assurance 质量保证QC Quality Control 质量控制QMP Quality Management Procedure 质量管理程序SDA State Drug Administration 国家药品监督管理局SMP Standard Managmert Procedure 标准管理程序SOP Standard Operating Procedure 标准操作程序TQC Tatal Quality Control 全面质量管理USA Uneted States Pharmacopeia 美国药典。
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME国际医药品稽查协约组织(PIC/S)2015年10月GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINALPRODUCTS良好生产规范药用产品的指南INTRODUCTION 简介General综述In order to further facilitate the removal of barriers to trade in medicinal products, to promote uniformity in licensing decisions and to ensure the maintaining of high standards of quality assurance in the development, manufacture and control of medicinal products, the following Guide to Good Manufacturing Practice for Medicinal Products and its Annexes has been adopted.为了进一步促进医药产品的贸易壁垒的去除,促进许可决定的一致性,确保质量保证在开发、制造和医药产品的控制方面高标准的维护,采用良好生产规范医药产品的以下指南及其附件。
The standards set out herein apply to medicines and similar products intended for human use. It is recommended, however, that the same kind of attention be given to the manufacture of veterinary products. Administrative measures of national health authorities should be directed towards the application of these standards in practice, and any new or amended national regulations for good manufacturing practice should at least meet their level. These standards are also intended to serve manufacturers as a basis for the elaboration of specific rules adapted to their individual needs.本标准的制定适用于供人类使用的药品和类似产品。
不过建议同样适用于兽药产品的生产。
国家卫生当局的行政措施应针对这些标准在实践中的应用,新的或修订GMP国家规范至少应该满足他们的要求。
这些标准也旨在为生产商作为特定规则的细化的基础适应他们的个人需求。
这些标准也旨在为生产商提供细化的特定规则为基础以适应他们的个人需求It is recognised that there are acceptable methods, other than those described in this Guide, which are capable of achieving the principles of the Guide. This Guide is not intended to place any restraint upon the development of new concepts or new technologies, which have been validated and provide a level of Quality Assurance at least equivalent to those set out in this Guide.除了本指南中描述的,还有其他可以接受的方法能够实现指南中的原则。
本指南并不想对新概念或新技术的发展进行任何限制,这些新概念或新技术已验证并提供至少相当于在本指南所述的质量保证水平。
The Guide is divided into two parts and a number of annexes which are common to both parts. Part I covers GMP principles for the manufacture of medicinal products. Part II covers GMP for active substances used as starting materials. The annexes provide detail on specific areas of activity. For some manufacturing processes, different annexes will apply simultaneously (e.g. annex on sterile preparations and on radiopharmaceuticals and/or on biological medicinal products). A glossary of some terms used in the Guide has been incorporated after the annexes. A specific glossary for APIs can be found at the end of Part II.该指南分为两部分和附件这常见的两个部分。
第一部分介绍医药产品生产的GMP原则。
第二部分介绍作为起始物料的活性物质的GMP。
附件提供活动的具体领域详情。
同时对于一些生产流程,将使用不同的附件(如附件无菌制剂和放射性药物和/或生物医药产品)。
指南中使用的术语的术语表编入附件后。
APIs的特定术语表在第二部分结尾可以找到。
History 历史Part I of the PIC/S GMP Guide PIC/S GMP指南的第一部分Originally, the PIC/S GMP Guide (“PIC Basic Standards” of 1972) derives from the WHO GMP Guide and was further developed in order to comply with stringent manufacturing and health requirements in PIC/S countries, to cover new areas (e.g. biologicals, radiopharmaceuticals, etc.) and to adapt to scientific and industrial technology (e.g. biotech, parametric release etc.). The aim of such improvements was to ensure that high quality medicines were produced in line with the PIC Convention and then the PIC Scheme.最初,PIC/S GMP指南(1972 PIC基本标准)源于WHO GMP指南,并为遵守严格的生产和PIC / S国家的卫生需求,覆盖新领域(如生物制剂、放射性药物等)和适应科学工业技术(如生物技术、参数版本等)进行进一步的发展。
这种改进的目的是确保高质量的药品生产符合PIC公约和PIC方案。
In 1989, the EU adopted its own GMP Guide, which – in terms of GMP requirements – was equivalent to the PIC/S GMP Guide. Since that time, the EU and the PIC/S GMP Guides have been developed in parallel and whenever a change has been made to one, the other has been amended so that both Guides are practically identical.在1989年,欧盟采用自己的GMP指南-依据GMP的要求-相当于PIC/S GMP 指南。
从此,欧盟和PIC/S GMP指南并行发展,只要一方做出变更,另一方会进行修订,因此这两个指南几乎是相同的。
There are, however, some differences between the two Guides. These differences are the following:然而,这两个指南也有一些差异。
这些差异如下:➢ the definition of Pharmaceutical Product (referred to as “Medicinal Product” in this Guide), which is found in Article 1 of the Pharmaceutical Inspection Convention, has been retained;医药产品的定义(在本指南称为“药品”)出现在药品检验公约的第一条,一直保留➢ references to the EU Directives, as well as to MRAs, have been deleted;引用欧盟指令,以及MRAs已经被删除了➢ the expression “authorised person” (see Glossary) is used in the PIC/S Guide while the expression “Qualified Person” is used in the EU Guide;“授权人”的表达(见术语表)在PIC/S指南中使用,而在欧盟指南中使用“有资质的人”;➢since not all Participating Authorities under the PIC Scheme are parties to the European Pharmacopoeia Convention, the mention of “European Pharmacopoeia” in the Guide has been amended to read “European or other relevant Pharmacopoeia”.因为按照PIC方案并不是所有参与部门是欧洲药典公约缔约方,指南中提到的“欧洲药典”已修改为“欧洲或其他相关药典”Part II of the PIC/S GMP Guide PIC/S GMP指南的第二部分On 22 May 2001, the PIC/S Committee adopted the “Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients” (ICH Q7A) developed by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) as a stand-alone guide (PE007). It is recalled that the first draft of this GMP Guide for APIs was elaborated by PIC/S, before it was transferred to ICH. At its Düsseldorf meeting on 29-30 May 2006, the PIC/S Committee decided to make it Part II of the current Guide.2001年5月22日,PIC/S委员会采用了“活性药物成分的良好生产规范指南”(ICH Q7A),人用药物注册技术要求国际协调会议(ICH)发展起来的作为一个独立的指导(PE 007)。